1. PW Noble, C Albera, WZ Bradford, U Costabel, MK Glassberg, D Kardatzke, TE King, L Lancaster, SA Sahn, J Szwarcberg, D. Valeyre, RM duBois, for the CAPACITY study group. Pirfenidone in patient with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet May 21;377(9779):1760-9. Epub 2011 May 13.
2. Pincus DJ, Kassira N, Gombosh M, Berho M, Glassberg MK, Karl M, Elliot SJ, and Thaller S. 17b-estradiol modifies diabetic wound healing by decreasing MMP activity. Wounds, 22 (7): 171-178, 2010.
3. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gomez-Marin O. Sildensfil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung Apr 188 (2): 115-23, 2010. Epub 2009 Dec 12.
4. Kassira N, , Glassberg MK, Jones C, Pincus D, Elliot SJ, Fritz JR, Karl M and Thaller S. Estrogen deficiency and tobacco smoke promote MMP-13 activation in skin of aging B6 mice. Annals of Plastic Surgery, 63(2):318-22, 2009.
5. Glassberg MK, Elliot SJ, Fritz J, Potier M, Donahue R, Stetler-Stevenson W, Karl M. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via MMP-induced cell invasiveness. Journal of Clinical Endocrinology and Metabolism, 19Feb 2008 (Epub).
6. Tattersfield AE, Glassberg MK. Lymphangioleiomyomatosis: a national registry for a rare disease. Am J Respir Crit Care Med;. 1;173 (1):2-4, 2006.
7. Glassberg MK. Improving early recognition of idiopathic pulmonary fibrosis. Pulmonary Perspectives in Chest (4): 5-8, 2004.
